The Potential Dangers of Thiazolidinediones
By Michele Wallace
Published on November 21, 2009
The medication class of thiazolidinediones (TZDs) was introduced to the U.S. market in the 1990s to treat type 2 diabetes. TZDs lower insulin resistance and blood sugar levels in patients and help the body regulate the metabolism of carbohydrates and fats.
Two TZD drugs are available to U.S. consumers: Avandia (rosiglitazone) and Actos (pioglitazone). Rezulin (troglitazone) was removed from the market after use of the drug was linked to an increase in the development of drug-induced hepatitis.
TZDs have been associated with some serious side effects. These include:
- Fluid retention
- Edema
- Weight gain
- Heart problems
- Liver problems
- Hypersensitivity
- Bone fractures
Several patients that have taken Avandia or Actos claim that they have suffered adverse health effects from use of these medications. Lawsuits against the manufacturers of these TZDs are pending.
Keyword Tags: